Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications

Authors

Carol H. Wysham
Carlos Campos
Davida F. Kruger, Henry Ford HealthFollow

Recommended Citation

Wysham CH, Campos C, and Kruger D. Safety and efficacy of insulin degludec/liraglutide (ideglira) and insulin glargine u100/lixisenatide (iglarlixi), two novel co-formulations of a basal insulin and a glucagon-like peptide-1 receptor agonist, in patients with diabetes not adequately controlled on oral antidiabetic medications. Clin Diabetes 2018; 36(2):149-159.

Document Type

Article

Publication Date

4-1-2018

Publication Title

Clin Diabetes

PubMed ID

29686454

Volume

36

Issue

2

First Page

149

Last Page

159